Canine Mesenchymal-Stem-Cell-Derived Extracellular Vesicles Attenuate Atopic Dermatitis

Area of Science:

• Veterinary Dermatology
• Regenerative Medicine
• Immunology

Background:

• Atopic dermatitis (AD) is a chronic inflammatory skin condition in dogs, often linked to systemic inflammation.
• Previous research demonstrated human adipose-tissue-derived mesenchymal stem cell extracellular vesicles (ASC-EVs) can reduce AD symptoms.
• Canine AD requires effective and safe therapeutic options.

Purpose of the Study:

• To evaluate the efficacy of canine ASC-derived exosomes (cASC-EVs) in a canine AD mouse model.
• To assess the in vivo toxicity and organ targeting of cASC-EVs.
• To explore the role of miRNAs within cASC-EVs in modulating inflammatory responses.

Main Methods:

• Isolation and characterization of canine ASCs and their derived EVs (cASC-EVs).
• Induction of AD-like symptoms in a mouse model and treatment with cASC-EVs.
• Assessment of clinical signs, serum IgE, ear thickness, cytokine/chemokine levels, and in vivo toxicity studies.
• Next-generation sequencing (NGS) analysis of miRNA content in cASC-EVs.

Main Results:

• cASC-EVs significantly improved AD-like dermatitis, reducing ear thickness and serum IgE levels.
• Treatment with cASC-EVs dose-dependently decreased key inflammatory cytokines like IL-4 and IFN-γ.
• No systemic toxicity or organ targeting was observed in toxicity studies with ICR mice.
• miRNA profiling revealed anti-inflammatory miRNAs within cASC-EVs.

Conclusions:

• Canine ASC-EVs are effective in attenuating canine AD symptoms through anti-inflammatory mechanisms.
• The therapeutic effect is mediated, in part, by the transfer of anti-inflammatory miRNAs.
• cASC-EVs represent a safe and promising cell-free therapeutic strategy for canine atopic dermatitis.